Cardiome Pharma in der analyse

So,Leute,ich bin auch wieder full on Bo(a)rd,nachdem ich Cardiome zwischenzeitlich verkauft hatte und einiges dummes Zeug angestellt hab mit einem einstieg bei Ariad und einen beinahe Totelverlust mit Getgoods,da war ich einfach rein,ohne irgendwelche Kennzahlen zu prüfen,mannomann,das soll mir eine Kehre sein. ! Jetzt aber zurück zu CRME : Nach der Übernahme halte ich Kurse von 100 Dollar/share auf längere sicht für möglich,ohne witz ......

MFG
Chali  

du weisst auch nicht was du willst...o.k. nachdem du immer sehr überzeugt
deinen Positionen vertrittst...nun meine Prognose:
wärste lieber mal in Ariad geblieben...die werden diesen Wert hier klar auf
6- Monatsdauer outperformen...dann kann man evtl. hier umschichten...

Iclusig wurde in Europa diese Woche klar bestätigt...und das letzte Wort mit
FDA ist da auch noch lang nicht gesprochen...Cash ist da...We will see:)  

Europace Publishes Data Supporting Use Of BRINAVESS™ (Vernakalant) As A First Line Agent For Pharmacological Cardioversion Of Atrial Fibrillation

13:50 21.11.13

PR Newswire

VANCOUVER, Nov. 21, 2013

NASDAQ: CRME   TSX: COM

VANCOUVER, Nov. 21, 2013 /PRNewswire/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced that a publication titled, Pharmacological Cardioversion of Atrial Fibrillation with Vernakalant: Evidence in Support of the ESC Guidelines, was published in Europace, the official Journal of the European Heart Rhythm Association, and was made available in the advanced online article access section. The authors conclude that BRINAVESS is an efficacious and rapid acting pharmacological cardioversion agent, for recent-onset atrial fibrillation (AF,) that can be used first line in patients with little or no underlying cardiovascular disease and in patients with moderate disease, such as stable coronary and hypertensive heart disease.

"The recent update of the ESC Guidelines on atrial fibrillation includes a discussion of the evidence base for the use of BRINAVESS and recommends its use as a first line agent for the conversion of AF to sinus rhythm," stated Dr. John Camm, Professor of Clinical Cardiology at St. George's University in London, UK.  "Based on completed clinical trials, BRINAVESS is effective, fast acting and well tolerated, and provides acute care physicians with an opportunity to pharmacologically cardiovert recent-onset AF patients including those with no or moderate structural heart disease."

In this publication, Savelieva et al., point out that pharmacological cardioversion would be the preferred method of converting patients from AF to sinus rhythm provided there was a safe, effective and fast acting pharmacological agent available on the market.  Older agents have treatment limitations, including contraindications which prevent use in structural heart disease for some, proarrhythmia or slow onset of action which may explain the need for longer hospital stays in others.

The authors of this publication explain that the benefits of pharmacological cardioversion include no need for general anaesthesia, conscious sedation, or fasting as well as a lower risk of immediate recurrence of AF and possibly lower psychological impact on some patients.  They point out that the choice of an antiarrhythmic drug for AF cardioversion is determined by the underlying heart disease.  In a subgroup analysis in 274 patients with ischaemic heart disease (41% with previous myocardial infarction) enrolled in ACT I-IV trials, no increased risk of serious adverse events was associated with BRINAVESS when compared to patients without ischaemic heart disease.  In addition, there were no drug related cases of torsade de pointes, ventricular fibrillation, or death in the subgroup with ischaemic heart disease, and the placebo-extracted efficacy of vernakalant was comparable (45.7% vs. 47.3% ischemic vs. non-ischaemic).

According to the 2012 focused update of the ESC Guidelines on the management of AF, BRINAVESS was granted a Class I recommendation with a level of evidence A for cardioversion of AF patients with structurally normal hearts or minimal heart disease and a Class IIb recommendation with a level of evidence B for cardioversion of AF patients with moderate structural heart disease.1,2  The development program for BRINAVESS has provided evidence to support recent recommendations, in the updated ESC Guidelines, to use the drug as a first line agent for the management of AF patients including those with moderate structural heart disease which is described as heart failure NYHA class I-II, stable coronary artery disease, and moderate left ventricular hypertrophy.

In this publication, the authors refer to a Buccelletti publication in which a meta-analysis of five controlled studies, (CRAFT, ACT I, ACT II, ACT III, AVRO) in 810 recent-onset AF patients, showed that BRINAVESS was 8.4 times more likely to convert AF to sinus rhythm when compared to placebo or amiodarone (95% CI, 4.4-16.3,) without excess risk of serious adverse events (risk ratio, 0.91; 95% CI, 0.6-1.36). Over 95% of patients that cardioverted to sinus rhythm after receiving BRINAVESS remained in sinus rhythm at 24 hours. Furthermore while discussing the efficacy of BRINAVESS, Savelieva et al., referred to a real world experience, observational study from a single centre in Malmö, Sweden, where the drug has been used in AF patients since 2011.  In this study 70% of 251 patients treated with BRINAVESS in the emergency room converted to sinus rhythm within 2 hours after start of the infusion with a median time to conversion of 11 minutes.

In the publication by Savelieva et al., BRINAVESS is presented as an efficacious, fast acting, and well tolerated pharmacological agent for the cardioversion of recent-onset AF with strong evidence supporting its recommendations for use in the ESC Guidelines for the Management of AF.

References:

   Savelieva, I. et al. Pharmacological Cardioversion of Atrial Fibrillation with Vernakalant: Evidence in Support of the ESC Guidelines. Europace. Advance access published Oct 9, 2013, doi: 10.1093/europace/eut274.
   Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH et al.  Focused Update of the ESC Guidelines for the Management of Atrial Fibrillation:  an Update of the 2010 ESC Guidelines for the Management of Atrial Fibrillation.  Europace.  2012; 14: 1385-413.

About Cardiome Pharma Corp.

Cardiome Pharma Corp. is a specialty biopharmaceutical company dedicated to the development and commercialization of new therapies that will improve the health of patients suffering from heart disease around the world. Cardiome has two marketed products, BRINAVESSTM (vernakalant IV), approved in Europe and other territories for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults, and AGGRASTAT® (tirofiban HCl) a reversible GP IIb/IIIa inhibitor indicated for use in Acute Coronary Syndrome patients.

Cardiome is traded on the NASDAQ Capital Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit www.cardiome.com.

Forward-Looking Statement Disclaimer

Certain statements in this news release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions.  Forward- looking statements may involve, but are not limited to, comments with respect to our objectives and priorities for the remainder of 2013 and beyond, our strategies or future actions, our targets, expectations for our financial condition and the results of, or outlook for, our operations, research and development and product and drug development. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such known risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions in the United States, Canada, Europe, and the other regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental legislation and regulations and changes in, or the failure to comply with, governmental legislation and regulations; availability of financial reimbursement coverage from governmental and third-party payers for products and related treatments; adverse results or unexpected delays in pre-clinical and clinical product development processes; adverse findings related to the safety and/or efficacy of our products or products; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to expand commercialization activities; and any other factors that may affect our performance. In addition, our business is subject to certain operating risks that may cause any results expressed or implied by the forward-looking statements in this presentation to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in our business strategy or development plans; intellectual property matters, including the unenforceability or loss of patent protection resulting from third-party challenges to our patents; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the availability of capital to finance our activities; and any other factors described in detail in our filings with the Securities and Exchange Commission available at www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com. Given these risks, uncertainties and factors, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

SOURCE Cardiome Pharma Corp  

Ich würde mich deiner Prognose nicht anschliessen,denn eines solltest du bedenken: Ariad hat nur einen Blockbuster,nämlich Iclusig,ist aber 10 mal so teuer wie Cardiome mit jetzt 2 blockbustern !

So what ?  

man muss auch gratulieren können...

Biotech ist immer ein sehr spekulatives Spiel...man weiß nie
welches Pferd der Gewinner wird...auch wie in meinem Fall nach 15 Jahren
Biotechanlagenerfahrung...aber nochmals Glückwunsch allen Investierten hier!  

Begrüssen wir mit der Gratulation auch gleich unseren Neuzugang doschauher,der sicher einen super einstand in der Aktie hat,wie gesagt,wir befinden uns an bord der U.S.S. Cardiome auf ihrem Weg "dausend Lichtjahre" von entenhausen entfernt ! Herzlich Willkommen:

 

ich bedanke mich erst mal bei Dir. Hättest Du nicht bei biometric was geschrieben, wär ich nicht drauf gekommen.  

 

Cardiome Pharma Corp. (CRME)
-NasdaqCM Follow

6.1001 Up 1.2201(25.00%) 3:09PM EST - Nasdaq Real Time Price  

Der Weltraum - unendliche Weiten... Wir schreiben das Jahr 2013. Dies sind die Abenteuer des Raumschiffs U.S.S. Cardiome, Das mit seiner inzwischen 335 Enten starken Besatzung seit 10 Jahren unterwegs ist, Um neue Welten zu erschließen, neues Leben und neue Herzmedikamente,die von Boardmediziner "Pille" eigens "State-of-the-art" entwickelt wurden. So dringt die Cardiome in Kursphantasien vor, die nie zuvor ein Mensch gesehen hat ......  

Bin jetzt erst mal mit einem schönen Plus raus, manchmal lohnt es sich doch wirklich zu warten, wie z.B. nach den letzten Zahlen. Der Anstieg war jetzt echt grandios. Gewinne sollte man ja auch mal mitnehmen. Viel Glück noch allen Investierten, ich hoffe, der Anstieg geht noch gut weiter. Beim nächsten Rücksetzer werde ich noch mal nachdenken.  

...allen Investierten hier...heut darf ich mich mal ein bisschen mitfreuen...
siehe ARIA...man weiß garnicht wo man hinschauen soll...alles so grün heute:)  

Sollte Chali doch Recht behalten? ;-)  

Moin ! Stellt sich bei dir die dicke Knete mit meinen tipps so langsam ein,hm ? Wenn noch nicht,dann kannst du eigentlich kaum was verkehrt machen hier,denn mein persönliches Kursziel für CRME liegt jetzt bei 100 Dollar anstatt 60 dollar !! Ich würde sogar aufstocken und dafür ONVO und AFFX verkaufen,ONVO hat eine schwere Bruchlandung zwischenzeitlich hingelegt ob der exorbitant hohen Bewertung,also zu Recht ! Ich werde,sobald es mir möglich ist ,CRME aufstocken,auch wenn wir ein Besatzungsmitglied verloren haben,das am Freitag die Rettungskapsel benutzt hat,warscheinlich weil er einem drohenden absturz der aktie zuvorkommen will,ich habe allerdings keinerlei Bedenken in diesee hinsicht,aber meine Meinung muss nicht massgeblich sein .......... schönes WE !  

gestern Abend nicht reingeschaut-und schon wieder rauf ;-))  

Da hat sich die Geduld doch ausgezahlt. Hoffe ich mal, dass Chalif mit seinen Kurszielen annähernd richtig liegt und die Amis wie letzte Woche weitermachen. Ami-Boards sind recht euphorisch.

Beim Rücksetzer etwas aufstocken. 80 Mill. $ MK erscheint doch etwas lächerlich.

Bin dabei. Viel Erfolg allen Investierten.

 

 

 

Ich kann mich in den Arschbeißen, daß ich vor 2,5 Wochen ausgestiegen bin (da lag der Kurs noch bei ca. € 3,30).

heute bin ich neu rein zu € 5,40.

Na ja, egal. Ich rechne - als longi - mit mindestens 500 % Rendite.

Da ist das zwar ärgerlich aber unterm Strich ok. (natürlich nur wenn das Potenzial so eintrifft, wie wir das erwarten).

Viel Erfolg allen Investierten und die noch dazukommen.

Moneyplus  

ja bereits 100 Mio. $ MK. So schnell geht das bei crme;-).

Ja, ein paar hundert Prozent wäre vor Weihnachten hilfreich (für die Nerven). Verkauft wird erst bei genannten Kurszielen ;-)

 

 

 

 

 

 

 

Ariad schiesst nach oben,völlig grundlos,denn das Medi ist nach wie vor vom Markt,wenn ich noch investiert wäre,würde ich jetzt schmeissen und hier bei CRME aufstocken,denn ARIA ist schon 1 MRD wert,hochgradige zockerei ......

Junge,junge !  

dass das nur eine gesunde Korrektur war ;-))